ICU Medical (IC7) Q2 2026 Earnings Report

The call conveyed a positive operational and financial trajectory: record revenues in key businesses, margin expansion, raised full-year guidance, and strong free cash flow enabled a $50M debt paydown and progress toward a ~2x leverage target. Headwinds remain — notably tariffs, currency impacts, restructuring charges, and a weakened Vital Care reported performance due to JV deconsolidation — and there is some timing uncertainty around regulatory resubmissions and project phasing. On balance, the company emphasized momentum and achievable margin/cash goals despite macro and one-time pressures.

ICU updated full‑year guidance, raising adjusted EBITDA to $415–$435 million (vs. prior $400–$430M) and adjusted EPS to $8.60–$9.00 (vs. prior $7.75–$8.45), and now expects full‑year adjusted gross margin of about 41.5%. Management assumes adjusted operating expenses of ~25% of revenue, net interest of ≈$65M, an adjusted tax rate of 25% and diluted shares of ~25.2M, and said the IV Solutions JV should be breakeven or a small loss for the year. They noted Q2 free cash flow of $62M (YTD $89M) and receipt of $20M in tariff refunds (Q2 tariff expense $8M, ≈1.5% of adjusted revenue), finished the quarter with $1.24B debt and $298M cash (net leverage 2.3x after a $50M paydown) and reiterated a target of roughly 2x leverage by year‑end. Guidance assumes a stable macro environment (inflation, currency and rates at current levels), the latest oil/diesel price forecast and no changes to current tariff policy; management also cited ongoing headwinds of ~$30–$40M of annual tariffs and ~ $60M of currency impact over the last four years.